Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

PDL Prior Authorization Criteria Revisions Scheduled for October 11, 2022

Last updated on

Beginning October 11, 2022, the Texas Health and Human Services Commission (HHSC) will revise step one of the preferred drug list (PDL) prior authorization criteria guides for the beta-agonist bronchodilator and the glucagon agent drug classes. These changes will modify the duration of treatment with a preferred agent in accordance with the Food and Drug Administration (FDA).

  • For the beta-agonist bronchodilator PDL criteria, step one will require a treatment failure after a 14-day trial with at least one preferred agent in the last 180 days. Currently, the PDL criteria requires a 30-day treatment trial with at least one preferred agent.
  • For the glucagon agent PDL criteria, step one will require a one-day treatment trial with at least one preferred agent in the last 180 days. Currently, the PDL criteria requires a 30-day treatment trial with at least one preferred agent.

These changes will help ensure quicker access to other effective treatment options for medications in those drug classes. The PDL prior authorization criteria are mandatory for managed care organizations.

Contact vdp-formulary@hhsc.state.tx.us with comments or any questions.